Surgery remains the key to progression-free survival in ovarian sex cord-stromal tumours
Two studies presented by the French network TMRG-GINECO provide new insights into the treatment and quality of life of women with this rare cancer
New therapies, new toxicities
Side-effects may occur at unpredictable timepoints during a patient’s treatment journey and even after treatment cessation
New FGFR inhibitors show potential for the treatment of cholangiocarcinoma
Two early studies investigate the anticancer activity of derazantinib and RLY-4008 in patients with FGFR inhibitor-naïve cholangiocarcinoma
Has TIL therapy the potential to change cancer treatment?
After TILs have shown benefits in advanced melanoma, many ‘synthetic biology’ strategies can be conceived to potentially extend this clinical signal to other patient groups
Overall survival data further support sacituzumab govitecan in HR+/HER2– metastatic breast cancer
Findings from the TROPiCS-02 trial show an overall survival benefit of sacituzumab govitecan in heavily pre-treated patients but raise questions about its optimal clinical implementation
How to integrate tebentafusp in the checkpoint-based clinical management of patients with uveal melanoma?
Since its approval, tebentafusp is changing the treatment landscape for patients with metastatic uveal melanoma, but many questions remain
AI and machine learning may change the course of translational research
However, according to the winner of the ESMO Award for Translational Research 2022, Dr Samra Turajlic, results will only be achieved through a collaborative effort of the oncology community
Lenvatinib plus pembrolizumab delays the time to deterioration of quality of life
In advanced pre-treated endometrial cancer, patient-reported outcomes support efficacy benefits of the combination therapy
Managing ovarian cancer in the PARP inhibitor era
The role of PARP inhibitors features in a number of sessions at the ESMO Gynaecological Cancers Congress 2022
Interim analysis shows that the safety of sacituzumab govitecan is in line with expectations
In the SASCIA trial, sacituzumab govitecan was associated with a higher incidence of adverse events and dose delays than treatment of physician’s choice in patients with HER2-negative breast cancer at high risk of relapse, but dose reductions occurred with a similar frequency in both arms